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ABSTRACT 
 
Oral tongue squamous cell carcinoma (OTSCC) is an aggressive disease frequently 
associated with poor prognosis due to the high risk of regional failure and mortality 
rates have been practically unchanged in Sweden the last fifty years, despite 
advancements in both diagnostics and treatment. 
Today we lack means to assess the biological aggressiveness of each individual 
tumor which varies largely. Treatment hinges on the International Union Against 
Cancer (UICC) TNM classification and comprises surgery with additional 
radio/chemotherapy in more advanced tumors. 
  
This thesis focuses on molecular biomarker expression in OTSCC. Increased 
knowledge paves the way to a more individualized cancer treatment aiming for better 
outcome and less overtreatment and sequele. 
 
The aim of this thesis was to investigate the predictive and prognostic value of 
quantitative DNA aberration, Ki-67, epidermal growth factor receptor (EGFR) and 
cyclooxygenase-2 (COX-2) in OTSCC. These biomarkers have all been found to 
influence carcinogenesis in head and neck cancer but little is known about their 
potential clinical role in OTSCC.  
We also wanted to evaluate outcome after elective neck dissection compared with 
observation of the neck in T1N0 OTSCC patients. 
 
A consecutive material consisting of biopsies taken from 78 OTSCC patients treated 
between the years 2000-2004 at Karolinska University Hospital in Stockholm 
Sweden were examined. Quantitative DNA aberration was analyzed using image 
cytometry. Immunohistochemistry (IHC) evaluating protein expression was 
performed on Ki-67, EGFR and COX-2. Furthermore EGFR gene copy number was 
investigated using fluorescence in situ hybridization (FISH).  
 
Results of these studies show that a high proliferative activity (Ki-67 expression) is 
associated with locoregional recurrence in stage I OTSCC. EGFR and COX-2 was 
overexpressed by IHC and high EGFR gene copy number was seen in OTSCC. 
Improved disease free and overall survival was found for patients when elective neck 
dissection was added to the primary treatment of T1N0 OTSCC.  
 
The high number of regional recurrence observed in patients with small tongue 
cancer with clinically negative necks resulted in a new treatment protocol. The head 
and neck group at Karolinska University Hospital has since 2006 included elective 
neck dissection to tumor resection in patients with T1N0 OTSCC. 
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